Results 51 to 60 of about 6,300,245 (266)
Clinical adenoviral gene therapy for prostate cancer
Prostate cancer is at present the most common malignancy in men in the Western world. When localized to the prostate, this disease can be treated by curative therapy such as surgery and radiotherapy. However, a substantial number of patients experience a
Schenk, Ellen +9 more
core +2 more sources
Background Acute lung injury (ALI) following pneumonia involves uncontrolled inflammation and tissue injury, leading to high mortality. We previously confirmed the significantly increased cargo content and extracellular vesicle (EV) production in ...
Yuna Bang +8 more
doaj +1 more source
Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity
Background Pre-clinical and clinical studies have shown that the infusion of CAR T cells with a naive-like (TN) and central memory (TCM) phenotype is associated with prolonged in vivo T cell persistence and superior anti-tumor effects.
Alejandro Torres Chavez +8 more
doaj +1 more source
Enteropathogenic E. coli (EPEC) infects the human intestinal epithelium, resulting in severe illness and diarrhoea. In this study, we compared the infection of cancer‐derived cell lines with human organoid‐derived models of the small intestine. We observed a delayed in attachment, inflammation and cell death on primary cells, indicating that host ...
Mastura Neyazi +5 more
wiley +1 more source
Redosing Adeno-Associated Virus Gene Therapy to the Central Nervous System
Adeno-associated virus (AAV)-mediated gene therapies have provided promising treatments for numerous neurological disorders. Redosing of AAV to the central nervous system (CNS) is an attractive research area due to both the somewhat immunologically ...
Arjomandnejad, Motahareh +4 more
core +1 more source
Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models
Cytokine release syndrome (CRS) is a significant side-effect of conventional chimeric antigen receptor (CAR) T-cell therapy. To facilitate patient accessibility, short-term (st) CAR T cells, which are administered to patients only 24 h after vector ...
Arezoo Jamali +5 more
doaj +1 more source
High expectations have been set on gene therapy with an AAV-delivered shortened version of dystrophin (µDys) for Duchenne muscular dystrophy (DMD), with several drug candidates currently undergoing clinical trials.
Anna V. Starikova +10 more
doaj +1 more source
Organoids in pediatric cancer research
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source
Editorial: Immunogenicity and toxicity of AAV gene therapy
Recombinant adeno-associated virus (AAV) is a promising delivery vehicle for in vivo gene therapy and has been widely tested in preclinical and clinical studies.
Bradbury, Allison +3 more
core +1 more source
An amendment to this paper has been published and can be accessed via the original article.
Camilo Breton +4 more
doaj +1 more source

